Prognosis in glomerulonephritis. III. A longitudinal analysis of changes in serum creatinine and proteinuria during the course of disease: effect of immunosuppressive treatment. Report from Copenhagen Study Group of Renal Diseases.
A total of 395 consecutive patients with biopsy-proven glomerulonephritis were followed up for 14 years. At the time of entry to the study the patients were classified as having one of nine states of kidney disease according to serum creatinine levels and proteinuria. The transitions of the patients between the nine states were analysed. The influence of 14 independent variables including treatment with cytostatic drugs and prednisolone was estimated by the Cox proportional hazard model. Treatment with immunosuppressive drugs had an influence that emerged within the first month and continued for the next 2 months. Subsequent treatment with cytostatic drugs in combination with prednisolone delayed further improvement. Treatment with prednisolone or cytostatic drugs as single therapy for up to 6 months increased the risk of improvement of the disease, and had no significant effect on deterioration. The beneficial effect of the treatment persisted after withdrawal of the immunosuppressive drugs. The analysis revealed only a slight influence of the histological character of the glomerular changes. Post-streptococcal glomerulonephritis carried an increased tendency for improvement. Arterial hypertension affected the process in several states of kidney disease. Heavy proteinuria increased the risk of increasing serum creatinine levels.
Brahm
M
M
Department of Nephrology, Herlev Hospital, Denmark.
Brammer
M
M
Balsløv
J T
JT
Brun
C
C
Jørgensen
H E
HE
Gerstoft
J
J
Lorenzen
I
I
Thomsen
A C
AC
D001379:Azathioprine / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003718:Denmark / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000188:drug therapy / Q000453:epidemiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D011379:Prognosis; D016016:Proportional Hazards Models; D011507:Proteinuria / Q000453:epidemiology*; D012307:Risk Factors; D013997:Time Factors
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone; D003404:Creatinine; D001379:Azathioprine